Zeting Yuan, Shuli Ma, Yue Li, Haowei Fang, Jing Shang, Yueping Zhan, Jie Wang, Teng Chen, Wanli Deng, Zhang Kunxi, Peihao Yin
Interventional Cancer Institute of Chinese Integrative Medicine & Putuo Hospital Shanghai University of Traditional Chinese Medicine Shanghai P. R. China.
Central Laboratory, Putuo Hospital Shanghai University of Traditional Chinese Medicine Shanghai P. R. China.
Bioeng Transl Med. 2023 Sep 18;8(6):e10576. doi: 10.1002/btm2.10576. eCollection 2023 Nov.
Developing effective therapy to inhibit postoperative recurrence and metastasis of colorectal cancer (CRC) is challenging and significant to reduce mortality and morbidity. Here, a granular hydrogel, assembled from gelatin microgels by dialdehyde starch and interpenetrated with in situ polymerized poly(sulfobetaine methacrylate--N-isopropylacrylamide) (P(SBMA--NIPAM)), is prepared to load and lock Food and Drug Administration (FDA)-approved indocyanine green (ICG) with definite photothermal function and biosafety for photothermal therapy (PTT) combining with checkpoint inhibitor. The presence of P(SBMA--NIPAM) endows granular hydrogel with high retention to water-soluble ICG, preventing easy diffusion and rapid scavenging of ICG. The ICG-locking granular hydrogel can be spread and adhered onto the surgery site at wet state in vivo, exerting a persistent and stable PTT effect. Combined with αPD-L1 treatment, ICG-locking granular hydrogel-mediated PTT can eradicate postsurgery residual and metastatic tumors, and prevent long-term tumor recurrence. Further mechanistic studies indicate that combination treatment effectively promotes dendritic cells maturation in lymph nodes, enhances the number and infiltration of CD8 T and CD4 T cells in tumor tissue, and improves memory T cell number in spleen, thus activating the antitumor immune response. Overall, ICG-locking gel-mediated PTT is expected to exhibit broad clinical applications in postoperative treatment of cancers, like CRC.
开发有效的疗法来抑制结直肠癌(CRC)术后复发和转移具有挑战性,但对于降低死亡率和发病率具有重要意义。在此,制备了一种颗粒水凝胶,它由明胶微凝胶通过二醛淀粉组装而成,并与原位聚合的聚(甲基丙烯酰氧乙基磺基甜菜碱-N-异丙基丙烯酰胺)(P(SBMA-NIPAM))互穿,用于负载并锁定美国食品药品监督管理局(FDA)批准的具有明确光热功能和生物安全性的吲哚菁绿(ICG),以用于光热疗法(PTT)并结合检查点抑制剂。P(SBMA-NIPAM)的存在赋予颗粒水凝胶对水溶性ICG的高保留性,防止ICG轻易扩散和快速清除。ICG锁定颗粒水凝胶在体内湿态下可铺展并粘附在手术部位,发挥持久稳定的PTT效应。与αPD-L1治疗相结合,ICG锁定颗粒水凝胶介导的PTT可根除术后残留和转移肿瘤,并防止长期肿瘤复发。进一步的机制研究表明,联合治疗可有效促进淋巴结中树突状细胞成熟,增加肿瘤组织中CD8 T细胞和CD4 T细胞的数量及浸润,并提高脾脏中记忆T细胞数量,从而激活抗肿瘤免疫反应。总体而言,ICG锁定凝胶介导的PTT有望在包括CRC在内的癌症术后治疗中展现广泛的临床应用。